Novel Methodology to Measure Protein Accumulation

Aging Clinical Trial

Official title:

Novel Methodology to Measure Protein Accumulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01505621
• Other study ID #: 11-004969
• Status: Completed
• Phase: N/A
• First received: January 4, 2012
• Last updated: April 9, 2014
• Start date: December 2011
• Est. completion date: August 2013

Study information

• Verified date: April 2014
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Accumulation of damaged proteins is thought to underlie many degenerative conditions, including aging, diabetes, Alzheimer's disease, cataracts, and others. Over time, proteins can be irreversibly damaged by a variety of factors, such as reactive oxygen species, and without timely degradation they can accumulate and aggregate. We believe this can contribute to the development of chronic degenerative disorders.

The purpose of this study is to develop a novel methodology for measuring protein accumulation and test it in two groups of people: young (18-30 years) and old (≥65 years). This methodology will require that people drink a solution of essential amino acids that includes isotopically labeled L[ring-13C6]phenylalanine. We will then collect blood and muscle samples, to isolate plasma and skeletal muscle proteins. Participants will return to the study center four more times on a weekly interval.

We hypothesize that older proteins, which persisted in circulation and accumulated over time, will have a higher degree of post-translational oxidative damage than newly synthesized proteins.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18-30 years

• Age greater than 65 years

Exclusion Criteria:

• Active or uncontrolled cardiovascular disease

• Chronic kidney disease with serum creatinine = 1.4 mg/dL for women and = 1.5 mg/dL for men

• Chronic liver disease (elevation in serum transaminases = 3 times the upper limit of normal)

• Any debilitating chronic illness, including malignancy

• Significant malabsorptive state, including prior gastric bypass surgery or inflammatory bowel disease

• Diabetes mellitus (types 1 or 2) or glucose = 110 mg/dL.

• Obesity (BMI = 31 kg/m2)

• Anticoagulant therapy (warfarin or heparin) or bleeding disorder that increases risk of bleeding during a muscle biopsy.

• Anemia (hemoglobin = 11 g/dL)

• Use of medications known to modulate protein synthesis, mitochondrial function, and/or glucose homeostasis (including ß-blockers and corticosteroids).

• Participation in another study where the 13CPhe was administered during the past 6 months.

• Moderate or high level of structured exercise (on average, = 30 minutes per day and = 2 days per week)

• Pregnancy

• Daily use of tobacco products (smoking or chewing); or smoking =7 cigarettes per week, on average. Abstinence from tobacco for =3 months is required before enrollment in the study.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Aging

Intervention

Other:
• L[ring-13C6]phenylalanine
Oral drink composed of essential amino acids including L[ring-13C6]phenylalanine

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Isotopic enrichment of plasma and skeletal muscle proteins achieved by oral ingestion of [13C6]-phenylalanine	Administration of an oral amino acid mixture containing isotopically-labeled [13C6]-phenylalanine (13C-Phe) will result in 13C-Phe incorporation into newly synthesized proteins. Measuring isotopic enrichment (IE) of 13C-Phe immediately after administration and weekly for 3 consecutive weeks will allow for estimation of protein accumulation.	3 weeks	No
Primary	Degree of post-translational modifications in plasma and muscle proteins	The abundance of post-translational modifications of plasma and muscle proteins will be measured using mass spectrometry.	3 weeks	No
Secondary	Assess differences in protein accumulation as a function of age	Use the newly developed methodology to assess whether otherwise healthy older adults (=65 years old) have greater accumulation of plasma and muscle proteins compared to healthy young adults (18-30 years old).	3 weeks	No
Secondary	Assess differences in protein modification/damage as a function of age	The abundance of post-translational modification/damage of plasma and muscle proteins will be measured using mass spectrometry in young (18-30 years old)and older (>65 years old) adults.	3 weeks	No